PPMS people - wake up!!! Your MS medication may be ready ...
Ocrelizumab, an experimental medication presently under investigation for the treatment of primary-progressive multiple sclerosis (PPMS), will be available for eligible individuals with PPMS through an Expanded Access Program (EAP). An EAP enables participants to receive an investigational medication that has not yet been approved by the United States Food and Drug Administration (FDA). This program is a nontraditional study that has no placebo group, so all those enrolled are given the active medication. It follows a strict protocol that has been developed through consultation with the FDA.
While 14 disease-modifying therapies are available for the treatment of relapsing forms of MS, no treatments have been approved by the FDA for PPMS, a less-common form of MS that is characterized by a steady accumulation of symptoms versus flare-ups and remissions. To take part in ocrelizumab’s EAP, individuals must meet the following specific study criteria:
- 18 to 55 years of age
- PPMS diagnosis
- Expanded Disability Status Score (EDSS) of 2.0 to 6.5 points
- Women of child-bearing potential will need to check with their program doctor about birth-control options
http://mymsaa.org/news/experimental-medication-ppms/
Ocrelizumab, an experimental medication presently under investigation for the treatment of primary-progressive multiple sclerosis (PPMS), will be available for eligible individuals with PPMS through an Expanded Access Program (EAP). An EAP enables participants to receive an investigational medication that has not yet been approved by the United States Food and Drug Administration (FDA). This program is a nontraditional study that has no placebo group, so all those enrolled are given the active medication. It follows a strict protocol that has been developed through consultation with the FDA.
While 14 disease-modifying therapies are available for the treatment of relapsing forms of MS, no treatments have been approved by the FDA for PPMS, a less-common form of MS that is characterized by a steady accumulation of symptoms versus flare-ups and remissions. To take part in ocrelizumab’s EAP, individuals must meet the following specific study criteria:
- 18 to 55 years of age
- PPMS diagnosis
- Expanded Disability Status Score (EDSS) of 2.0 to 6.5 points
- Women of child-bearing potential will need to check with their program doctor about birth-control options
http://mymsaa.org/news/experimental-medication-ppms/
Thanks for the info Marco. (I don't qualify, unfortunately)
Comment